We hypothesized that PSA persistence (>0.1 mg/mL) at 4–8 weeks would influence these oncologic and survival outcomes in PCa patients treated with RP and there are no systematic reviews and meta-analyses on this topic at this moment. The gene discussed is KLK3; the disease is posterior cortical atrophy.